Nevanac(nepafenac)
Ilevro, Nevanac (nepafenac) is a small molecule pharmaceutical. Nepafenac was first approved as Nevanac on 2005-08-19. It is used to treat eye pain in the USA. It has been approved in Europe to treat ophthalmologic surgical procedures and postoperative pain.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Ilevro, Nevanac
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
54 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cataract | D002386 | EFO_0001059 | H26.9 | — | 5 | 8 | 11 | 2 | 26 |
| Macular edema | D008269 | — | — | — | 4 | 1 | 7 | 1 | 13 |
| Inflammation | D007249 | MP_0001845 | — | — | 1 | 4 | 4 | 1 | 10 |
| Edema | D004487 | — | R60.9 | — | 2 | 1 | 5 | — | 8 |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | — | 1 | 2 | 4 |
| Intraocular pressure | D007429 | — | — | — | — | — | 2 | — | 2 |
| Myopia | D009216 | EFO_0003927 | H52.1 | — | — | — | 1 | 1 | 2 |
| Cataract extraction | D002387 | — | — | — | — | — | 2 | — | 2 |
| Retinal vein occlusion | D012170 | EFO_1001157 | H34.81 | — | — | — | 1 | — | 1 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | — | 1 | — | 1 |
Show 9 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetic retinopathy | D003930 | EFO_0003770 | — | — | 2 | 3 | — | — | 5 |
| Retinal diseases | D012164 | — | H35.9 | — | 2 | 2 | — | — | 4 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Miosis | D015877 | — | H57.03 | — | 1 | — | — | — | 1 |
| Phacoemulsification | D018918 | — | — | — | 1 | — | — | — | 1 |
| Fuchs' endothelial dystrophy | D005642 | EFO_0003946 | H18.51 | — | 1 | — | — | — | 1 |
| Bacterial conjunctivitis | D003234 | EFO_1000829 | H10.0 | — | 1 | — | — | — | 1 |
| Conjunctivitis | D003231 | — | H10 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glaucoma | D005901 | EFO_0000516 | H40 | — | — | — | — | 1 | 1 |
| Angle-closure glaucoma | D015812 | — | — | — | — | — | — | 1 | 1 |
| Pain management | D059408 | — | — | — | — | — | — | 1 | 1 |
| Postoperative care | D011182 | — | — | — | — | — | — | 1 | 1 |
| Papilledema | D010211 | EFO_1001074 | H35.81 | — | — | — | — | 1 | 1 |
| Central serous chorioretinopathy | D056833 | — | H35.71 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nepafenac |
| INN | nepafenac |
| Description | Nepafenac is a monocarboxylic acid amide that is amfenac in which the carboxylic acid group has been converted into the corresponding carboxamide. It is a prodrug for amfenac, used in eye drops to treat pain and inflammation following cataract surgery. It has a role as a prodrug, a cyclooxygenase 2 inhibitor, a cyclooxygenase 1 inhibitor, a non-steroidal anti-inflammatory drug and a non-narcotic analgesic. |
| Classification | Small molecule |
| Drug class | anti-inflammatory agents (acetic acid derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N |
Identifiers
| PDB | — |
| CAS-ID | 78281-72-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1021 |
| ChEBI ID | 75922 |
| PubChem CID | 151075 |
| DrugBank | DB06802 |
| UNII ID | 0J9L7J6V8C (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Nepafenac
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,002 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,141 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use